http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 14:25:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and import authorization from the UK Home Office. The company stated it intends to announce the trial partner and indication at a later date.</p> <p>"This is our first shipment into the United http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629359.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment included psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was completed under authorization from Health Canada and the UK Home Office. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient using proprietary methods under its Health Canada Drug Establishment Licence.</p> <p>"This is http://www.streetinsider.com/FDA/Optimi+Health+ships+first+psilocybin+export+to+UK+for+phase+2+trial/26629360.html Wed, 10 Jun 2026 14:25:35 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html <p>Optimi Health Corp. (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial, the company announced.</p> <p>The shipment includes psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression.</p> <p>The export was conducted under authorization from Health Canada and import authorization from the UK Home Office. Optimi stated it intends to announce the trial partner and indication at a later date.</p> <p>The company cultivated the biomass and produced the capsules http://www.streetinsider.com/FDA/Optimi+Health+exports+psilocybin+to+UK+for+phase+2+clinical+trial/26629358.html Wed, 10 Jun 2026 14:25:28 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html <div class="xn-content"> <p class="prntac"><i>The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> and was completed under export authorization from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> and import authorization from the <span>UK Home Office</span></i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4708756-1&amp;h=361802252&amp;u=https%3A%2F%2Foptimihealth.ca%2F%3Futm_source%3Dchatgpt.com&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+First+Export+of+Psilocybin+to+the+United+Kingdom+for+Phase+2+Clinical+Trial/26629357.html Wed, 10 Jun 2026 14:24:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI